Lundbeck CEO remains optimistic despite flagship product's Q4 setback
Despite disappointing sales in the fourth quarter from antidepressant Trintellix/Brintellix, drugmaker Lundbeck is still expecting the key product to grow, informs the company’s chief exec, Deborah Dunsire, to MedWatch.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck's new long-term goals reflect growth confidence
For subscribers
Lundbeck CEO's pay package halved after dull stock year
For subscribers